Shi Jichan, Gao Gexin, Pan Jing, Wu Lian-Peng, Ning Hongye, Wu Zhengxin, Ye Xinchun, Jiang Xiangao
Department of Infectious Disease, The Theorem Clinical College of Wenzhou Medical University, Wenzhou Central Hospital, Wenzhou, People's Republic of China.
Department of Nursing, Wenzhou Medical University, Wenzhou, People's Republic of China.
Infect Drug Resist. 2023 Jul 17;16:4635-4643. doi: 10.2147/IDR.S405563. eCollection 2023.
To evaluate the clinical value of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) in detecting ().
The clinical data of 172 patients with suspected lung disease were collected from our hospital from January 1, 2018, to December 30, 2021. The results were compared with those of BACTEC MGIT 960 in liquid culture and gene chip. This study also utilised MALDI-TOF MS to detect macrolide (MA) and amikacin (Am) mutations.
One hundred thirty-seven cases of pulmonary disease were confirmed by identifying the gene chip in bronchoalveolar lavage fluid and/or MALDI-TOF MS detection. The positive predictive value and negative predictive value were 100% (131/131) and 85.37% (35/41), respectively, and the consistency of the two methods was high (kappa=0.899). For the drug resistance detection of MAs, the consistency rate between MALDI-TOF MS detection and drug sensitivity detection was 97.71% (128/131), the sensitivity was 81.25% (13/16) and the specificity was 100% (115/115). The positive and negative predictive values were 100% (13/13) and 93.75% (115/118), respectively. There was no coincidental consistency between the two methods, and the consistency was high (P<0.001, kappa=0.884). For the drug resistance test of Am, the consistency rate between the MALDI-TOF MS test and the drug sensitivity test was 93.13% (122/131), the sensitivity was 93.52% (101/108), the specificity was 90.91% (21/23) and the positive predictive value and negative predictive value were 98.06% (101/103) and 75.00% (21/28), respectively. The two methods had high consistency, and the consistency was not coincidental (P<0.001, kappa=0.781).
Utilising MALDI-TOF MS has a good consistency with the drug resistance gene chip method and can be a rapid and effective method to identify strains and drug resistance of . Therefore, it has certain clinical application value in patients with suspected lung disease.
评估基质辅助激光解吸/电离飞行时间质谱(MALDI-TOF MS)在检测()方面的临床价值。
收集我院2018年1月1日至2021年12月30日172例疑似肺部疾病患者的临床资料,并与液体培养中的BACTEC MGIT 960及基因芯片检测结果作比较。本研究还利用MALDI-TOF MS检测大环内酯(MA)和阿米卡星(Am)突变情况。
通过支气管肺泡灌洗液中的基因芯片鉴定和/或MALDI-TOF MS检测确诊137例肺部疾病。阳性预测值和阴性预测值分别为100%(131/131)和85.37%(35/41),两种方法的一致性较高(kappa=0.899)。对于MA的耐药性检测,MALDI-TOF MS检测与药敏检测的符合率为97.71%(128/131),灵敏度为81.25%(13/16),特异性为100%(115/115)。阳性和阴性预测值分别为100%(13/13)和93.75%(115/118)。两种方法无偶然一致性,一致性较高(P<0.001,kappa=0.884)。对于Am的耐药性检测,MALDI-TOF MS检测与药敏检测的符合率为93.13%(122/131),灵敏度为93.52%(101/108),特异性为90.91%(21/23),阳性预测值和阴性预测值分别为98.06%(101/103)和75.00%(21/28)。两种方法一致性较高,且一致性并非偶然(P<0.001,kappa=0.781)。
MALDI-TOF MS与耐药基因芯片方法具有良好的一致性,可作为快速有效的方法用于鉴定()的菌株及耐药情况。因此,其在疑似肺部疾病患者中具有一定的临床应用价值。